Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime-Boost of BBV152 and BBV154 in Healthy Volunteers
NCT05639998Phase 2Completed
- Sponsor
- Bharat Biotech
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iNCOVACC in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Bharat Biotech. Primary endpoint: Neutralizing antibody titer against SARS-CoV-2 at Day 180. Started Sep 2021; status: completed.
02
Drugs
iNCOVACC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05639998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639998.